Navigation Links
GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
Date:1/7/2009

LONDON, Jan. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB). The tender offer expired at 12:00 midnight, New York City time, on Tuesday, January 6, 2009.

The depositary for the tender offer has advised GSK that shareholders of Genelabs have tendered and not withdrawn a total of approximately 39,250,243 shares of Genelabs common stock. These shares, together with the shares beneficially owned by GSK and its wholly-owned subsidiaries, represent approximately 88.55 percent of the outstanding shares of Genelabs on a fully diluted basis. Gemstone has accepted for payment all Genelabs shares tendered in the offer.

GSK also announced that Gemstone exercised its "top-up" option in accordance with the previously announced merger agreement with Genelabs. The exercise of the top-up option allowed Gemstone to increase its share ownership percentage of Genelabs through the purchase of newly-issued shares of Genelabs common stock at the tender offer price. As a result, Gemstone owns more than 90 percent of the outstanding shares of Genelabs common stock and intends to effect a short-form merger as promptly as practicable, without the need for a meeting of Genelabs shareholders. In the merger, Gemstone will acquire all other Genelabs shares (other than those as to which holders properly exercise dissenters' rights) at the same $1.30 per share price, without interest and less any required withholding taxes, that was paid in the tender offer. As a result of the merger, Genelabs will become a wholly-owned subsidiary of GSK and Genelabs shares will cease to be traded on The NASDAQ Capital Market.

About GlaxoSmithKline plc

GlaxoSmithKline plc -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information including a copy of this announcement and details of the company's updated product development pipeline, visit GSK at www.gsk.com.

    Enquiries:
    UK Media enquiries:                  Philip Thomson  (020) 8047 5502
                                         Alice Hunt      (020) 8047 5502
                                         Stephen Rea     (020) 8047 5502

    US Media enquiries:                  Nancy Pekarek    (919) 483 2839
                                         Mary Anne Rhyne  (919) 483 2839
                                         Sarah Alspach    (215) 751 7709
                                         Melinda Stubbee  (215) 751 7709

    European Analyst/Investor enquiries: David Mawdsley  (020) 8047 5564
                                         Sally Ferguson  (020) 8047 5543
                                         Gary Davies     (020) 8047 5503

    US Analyst/ Investor enquiries:      Tom Curry        (215) 751 5419
                                         Jen Hill         (215) 751 7002


'/>"/>
SOURCE GlaxoSmithKline plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
10. Vaccinex Antibody Licensed to GlaxoSmithKline
11. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... (d/b/a Biohaven) is pleased to announce the appointment of John Tilton as Chief Commercial ... Executive Director and one of the founding commercial leaders responsible for the commercialization ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan Ross, ... Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology from ... and the suppression of graft vs. host disease (GVHD) under UM Professor Robert Levy ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron Cushman has ... associate in the firm’s Intellectual Property practice group. , Clients turn to Cushman ... He has an electrical engineering and computer engineering background, and experience in the ...
(Date:4/26/2016)... ... 26, 2016 , ... Mr. Palmer created the RPO business for Ceridian and ... multi-year managed services contract in the U.S. intelligence community with The SI (a Lockheed ... John Younger, founder of Accolo. “We are growing and his experience guiding our ...
Breaking Biology Technology:
(Date:3/9/2016)... 2016 This BCC Research report provides an ... RNA Sequencing (RNA Seq) market for the years 2015, ... and reagents, data analysis, and services. Use ... RNA-Sequencing market such as RNA-Sequencing tools and reagents, RNA-Sequencing ... affecting each segment and forecast their market growth, future ...
(Date:3/3/2016)... 3, 2016  FlexTech, a SEMI Strategic Association Partner, ... Research & Development, Leadership in Education, and, in a ... 9 th year of the FLEXI Awards and ... individuals from past years . Judging was done ... set of criteria, by a panel of non-affiliated, independent, ...
(Date:3/2/2016)... 2, 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ... as a Service Market 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ...
Breaking Biology News(10 mins):